Bavencio 20 mg/mL concentrate for solution for infusion
Product Information *
Company:
Merck - PfizerStatus:
No Recent UpdateActive Ingredients :
This medicinal product is subject to additional monitoring.
*Additional information is available upon request
Legal Category:
Product subject to medical prescription which may not be renewed (A)
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 26 January 2021
File name
Bavencio PIL - TW2494580, TW2669961 - Jan 2021 - clean_1611678412.pdf
Reasons for updating
- Change to section 1 - what the product is used for
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
Changes include: Addition of new indication - urothelial carcinoma (UC) & shelf life extension to 3 years.
Our ref: TW2494580, TW2669961
Updated on 26 January 2021
File name
Bavencio SPC 20mgml UK&IE TW2494580 TW2669961 current v9.0 - clean_1611678282.pdf
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 6.3 - Shelf life
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Changes include: Addition of new indication - urothelial carcinoma (UC) & shelf life extension to 3 years.
Our ref: TW2494580, TW2669961
File name
Bavencio Patient Info Brochure A5 Ireland Sept2020 v1_1602496034.pdf
Reasons for updating
- Replace File
Free text change information supplied by the pharmaceutical company
Updated with immune-related adverse event myasthenia gravis
File name
Bavencio Patient alert card 55x85mm Ireland Sept2020 v1_1602496034.pdf
Reasons for updating
- Replace File
Free text change information supplied by the pharmaceutical company
Updated with immune-related adverse event myasthenia gravis
Updated on 29 September 2020
File name
Bavencio 20mgml UK&IE TW2351837 TW2263689 PIL_1601383201.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
- Addition of myasthenia gravis as an immune-related adverse event
- Removal of the ‘conditional’ status of the Marketing Authorisation
Our ref:
TW2351837
TW2263689
Updated on 29 September 2020
File name
Bavencio 20mgml UK&IE TW2351837 TW2263689 TW2350918 current v8.0_1601382994.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 9 - Date of first authorisation/renewal of the authorisation
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
- Addition of myasthenia gravis as an immune-related adverse event
- Addition of MCC ‘Part B’ data (specific obligation) and removal of the ‘conditional’ status of the Marketing Authorisation in section 5.1
- 3rd annual renewal of the Marketing Authorisation
Our ref:
TW2351837
TW2263689
TW2350918
File name
MCC Bavencio Patient Info Brochure A5 Ireland Nov19 v2_1575294803.pdf
Reasons for updating
- Replace File
Updated on 31 October 2019
File name
PIL RCC_1572521281.pdf
Reasons for updating
- Change to section 1 - what the product is used for
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 3 - dose and frequency
- Change to section 3 - how to take/use
- Change to section 3 - duration of treatment
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
Updated on 31 October 2019
File name
Bavencio 20mgml UK&IE TW1972145 current v7_1572521052.pdf
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 9 - Date of first authorisation/renewal of the authorisation
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
File name
Final MCC Bavencio Patient Info Brochure A5 Ireland July19 v2 - Panc_1564056319.pdf
Reasons for updating
- Replace File
File name
Final MCC Bavencio Patient alert card 55x85mm Ireland Jul19 v2 - Panc_1564056304.pdf
Reasons for updating
- Replace File
Updated on 08 July 2019
File name
Bavencio - Package leaflet - Panctreatitis - TW1972347_1562576354.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
Updated on 05 July 2019
File name
Bavencio 20mgml UK&IE TW1972347 current v6.0_1562323520.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 9 - Date of first authorisation/renewal of the authorisation
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
File name
Patient alert card 55x85mm Ireland v4_1559296145.pdf
Reasons for updating
- Add New Doc
File name
Bavencio Patient Info Brochure A5 Ireland v4_1559296190.pdf
Reasons for updating
- Add New Doc
Updated on 09 April 2019
File name
Bavencio_corrigendum_PIL_1554816824.pdf
Reasons for updating
- Change to section 6 - date of revision
- Change to other sources of information section
Updated on 15 February 2019
File name
Bavencio 20mgml UK&IE TW1971395 current v5.0_1550226543.pdf
Reasons for updating
- Change to section 9 - Date of first authorisation/renewal of the authorisation
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 20 September 2018
File name
Bavencio 20mgml UK and IE TW1767401 current v4.0_1537429420.pdf
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 17 July 2018
File name
PIL_17313_183.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 17 July 2018
File name
Bavencio 20mgml UK and IE TW1735675 current v3.0 (002).docx
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 03 January 2018
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 03 January 2018
Reasons for updating
- Change to section 6.3 - Shelf life
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
5.1 Pharmacodynamic properties- ATC code has changed from not yet assigned to L01XC31.
6.3 Shelf life - Under, After preparation of infusion, '(see section 6.6)' has been removed.
6.6 Special precautions for disposal and other handling - 'The diluted solution must not be stored longer than a total of 24 hours under refrigerated conditions, (2°C to 8°C) or up to 8 hours at room temperature (20°C to 25°C)' has been removed.
10. DATE OF REVISION OF THE TEXT - has changed to 12/2017
Updated on 02 January 2018
File name
PIL_17313_183.pdf
Reasons for updating
- New PIL for new product
Updated on 02 January 2018
Reasons for updating
- Change to section 6 - date of revision
- Change to information for healthcare professionals
Updated on 27 September 2017
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 27 September 2017
Reasons for updating
- New PIL for new product